Skip to main content

Abbott's MDx Sales Rise 23 Percent in Q2 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott Laboratories today reported 18 percent revenue growth overall for the second quarter ended June 30, and a 23 percent increase in sales of its molecular diagnostic products.

The diagnostics and pharmaceuticals giant reported Q2 sales of $89 million for its molecular diagnostic products, of which $43 million was derived from US sales and the remainder from international markets.

Late in the second quarter, Abbott received US Food and Drug Administration clearance for its molecular diagnostic test for detecting gonorrhea and chlamydia, including a new strain of chlamydia recently discovered in Sweden, and its m2000 molecular diagnostic system.

Abbott said in a statement that it expects to launch more than 12 new molecular diagnostic products over the next two to three years, including several cancer and infectious disease tests, as well as improved instrument systems.

Overall, Abbott reported Q2 revenues of $8.8 billion, up from $7.5 billion for Q2 2010. Its net earnings were flat year over year at $1.29 billion, or $.83 per share.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.